As we await the results of the Phase II trials it would be great to gain an understanding of the companies commercial strategy for commercialisation of the treatment.
If others feel that the Market needs to be better informed of the commercialisation and roll out plans then I suggest we email Racheal Joel from Public Relations, who kindly replied that she would pass on questions and concerns to management. mailto:[email protected]
Like others I believe LCT could be updating the market on the Business strategy, Otherwise the time span between updates will cripple the SP. The Markets assimilate no news with no action, but I'm sure there are relationships that LCT can begin to announce and how the roll out will occur,,, OBVIOUSLY all conditional to positive results from the current trials.
LCT Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
